Because the Intelligence Community utilizes commercial products including those that may be manufactured abroad, it could be vulnerable to threat or compromise through its supply chain. Intelligence Community Directive 731 issued by Director of National Intelligence James Clapper on December 7 establishes IC policy on “Supply Chain Risk Management.”
“Many IC mission-critical products, materials, and services come from supply chains that interface with or operate in a global marketplace. A greater understanding of the risks inherent in the IC’s participation in the global market place is crucial to safeguarding our nation’s intelligence sources, methods, and activities,” the Directive said.
“Supply chain risk management is the management of risk to the integrity, trustworthiness, and authenticity of products and services within the supply chain.”
“It addresses the activities of foreign intelligence entities … and any other adversarial attempts aimed at compromising the IC supply chain, which may include the introduction of counterfeit or malicious items into the IC supply chain,” the Directive said.
DNA synthesis and export controls remain the primary regulatory safeguards against de novo production of harmful biological agents, yet governance frameworks lack the situational awareness and enforcement capacity to keep pace with rapidly falling technical barriers.
Called today to speak on behalf of U.S. science and technology, Dr. Jedidah Isler, astrophysicist, educator, strategist, policy-maker, and science communicator, will provide constructive, nonpartisan feedback to the House Committee’s hearing “American Global Competitiveness at 250: Legislative Proposals to Secure U.S. Technology Leadership.”
“Federal data and access to it is not a partisan issue. It is a people issue. Our country cannot achieve greatness without access to the data that measure what we value, who we are, and where we’re heading.”
The United States’ biosecurity governance system is structurally incapable of detecting and responding to certain classes of threats. U.S. biosecurity tools have not kept pace with technological advancements or a changing threat landscape.